Lukas Makris

3.5k total citations
64 papers, 1.0k citations indexed

About

Lukas Makris is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Lukas Makris has authored 64 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 15 papers in Surgery. Recurrent topics in Lukas Makris's work include Colorectal Cancer Treatments and Studies (25 papers), Gastric Cancer Management and Outcomes (17 papers) and Cancer Treatment and Pharmacology (12 papers). Lukas Makris is often cited by papers focused on Colorectal Cancer Treatments and Studies (25 papers), Gastric Cancer Management and Outcomes (17 papers) and Cancer Treatment and Pharmacology (12 papers). Lukas Makris collaborates with scholars based in United States, Italy and Japan. Lukas Makris's co-authors include Ewa Rucinska, Najam A. Awan, Kenneth Dickstein, John G.F. Cleland, Hamid Ikram, James B. Young, George Klinger, Martin Frey, Ian Crozier and Allan I. Goldberg and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Journal of the American College of Cardiology.

In The Last Decade

Lukas Makris

59 papers receiving 952 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lukas Makris United States	15	454	264	208	180	169	64	1.0k
Hiromitsu Iwamoto Japan	20	394 0.9×	286 1.1×	333 1.6×	364 2.0×	266 1.6×	54	1.5k
Minh Duong-Hua Canada	9	172 0.4×	239 0.9×	383 1.8×	91 0.5×	200 1.2×	11	877
Álex de la Sierra Spain	12	269 0.6×	251 1.0×	94 0.5×	122 0.7×	108 0.6×	16	830
Michael J. Bloch United States	12	179 0.4×	121 0.5×	145 0.7×	81 0.5×	164 1.0×	63	692
Thomas A. Sellers United States	11	143 0.3×	381 1.4×	68 0.3×	117 0.7×	267 1.6×	13	1.2k
Leslie A. Garrett United States	17	223 0.5×	134 0.5×	91 0.4×	180 1.0×	99 0.6×	38	1.1k
Lixin Meng United States	12	259 0.6×	263 1.0×	145 0.7×	65 0.4×	53 0.3×	14	922
Debra L. Simmons United States	17	195 0.4×	155 0.6×	56 0.3×	209 1.2×	478 2.8×	39	1.1k
Alan Bell Canada	14	342 0.8×	208 0.8×	135 0.6×	270 1.5×	78 0.5×	53	997
Meir J. Stampfer United States	8	258 0.6×	71 0.3×	161 0.8×	188 1.0×	174 1.0×	9	1.3k

Countries citing papers authored by Lukas Makris

Since Specialization

Citations

This map shows the geographic impact of Lukas Makris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lukas Makris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lukas Makris more than expected).

Fields of papers citing papers by Lukas Makris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lukas Makris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lukas Makris. The network helps show where Lukas Makris may publish in the future.

Co-authorship network of co-authors of Lukas Makris

This figure shows the co-authorship network connecting the top 25 collaborators of Lukas Makris. A scholar is included among the top collaborators of Lukas Makris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lukas Makris. Lukas Makris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blom, Dirk, James Underberg, Christopher P. Cannon, et al.. (2025). Real-world safety and effectiveness of lomitapide in homozygous familial hypercholesterolaemia over ten years: Data from the lomitapide observational worldwide evaluation registry (LOWER). Atherosclerosis. 407. 119610–119610.

Blom, Dirk, James Underberg, Christopher P. Cannon, et al.. (2024). The long-term, real-world effectiveness and safety of lomitapide in homozygous familial hypercholesterolaemia (HoFH): Nine-year data from the lomitapide observational worldwide evaluation registry (lower). Atherosclerosis. 395. 118517–118517. 1 indexed citations

Underberg, James, Christopher P. Cannon, Dominique Larrey, et al.. (2024). The Lomitapide Observational Worldwide Evaluation Registry (LOWER) - Nine-year Effectiveness and Safety Data in HoFH. Journal of clinical lipidology. 18(4). e545–e545.

Minchom, Anna, Edward G. Garmey, Lukas Makris, et al.. (2024). 680TiP A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies. Annals of Oncology. 35. S530–S530. 1 indexed citations

Shitara, Kohei, Ben George, Julien Taı̈eb, et al.. (2023). Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS). Journal of Cancer Research and Clinical Oncology. 149(11). 9361–9374. 1 indexed citations

Mansoor, Wasat, Hendrik‐Tobias Arkenau, María Alsina, et al.. (2021). Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study. Gastric Cancer. 24(4). 970–977. 6 indexed citations

Varghese, Anna M., Dana B. Cardin, Al B. Benson, et al.. (2020). Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. Clinical Cancer Research. 26(7). 1555–1562. 13 indexed citations

Underberg, James, et al.. (2020). LONG-TERM SAFETY AND EFFICACY OF LOMITAPIDE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: FIVE-YEAR DATA FROM THE LOMITAPIDE OBSERVATIONAL WORLDWIDE EVALUATION REGISTRY (LOWER). Journal of the American College of Cardiology. 75(11). 1992–1992. 1 indexed citations

Underberg, James, et al.. (2020). Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER). Journal of clinical lipidology. 14(6). 807–817. 52 indexed citations

10.

Yamamoto, Nobuyuki, Hidetoshi Hayashi, David Planchard, et al.. (2020). A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer. Investigational New Drugs. 38(5). 1588–1597. 13 indexed citations

11.

Underberg, James, Christopher P. Cannon, Dominique Larrey, et al.. (2018). LONG-TERM SAFETY AND EFFICACY OF LOMITAPIDE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: THREE-YEAR DATA FROM THE LOMITAPIDE OBSERVATIONAL WORLDWIDE EVALUATION REGISTRY (LOWER). Journal of the American College of Cardiology. 71(11). A168–A168. 2 indexed citations

12.

Arkenau, Hendrik‐Tobias, Josep Tabernero, Kohei Shitara, et al.. (2018). TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer. Annals of Oncology. 29. viii718–viii718. 1 indexed citations

13.

Cutsem, Eric Van, R. Mayer, Stéphanie Laurent, et al.. (2017). The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. European Journal of Cancer. 90. 63–72. 62 indexed citations

14.

Underberg, James, et al.. (2016). Abstract 12117: Global Real-World Data on the Use of Lomitapide in Treating Homozygous Familial Hypercholesterolemia: The Lomitapide Observational Worldwide Evaluation Registry (LOWER), Two-Year Data. Circulation. 134(suppl_1).

15.

Tabernero, Josep, Atsushi Ohtsu, Takayuki Yoshino, et al.. (2016). PD-025 RECOURSE trial: impact of adverse events on quality of life and duration of TAS-102 (trifluridine and tipiracil) treatment. Annals of Oncology. 27. ii111–ii111. 3 indexed citations

16.

Blom, Dirk, et al.. (2015). LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design. Journal of clinical lipidology. 10(2). 273–282. 35 indexed citations

17.

Krauss, Juergen, M. E. Scheulen, Dirk Strumberg, et al.. (2009). Pharmacokinetic study of S-1. International Journal of Clinical Pharmacology and Therapeutics. 47(1). 65–67. 2 indexed citations

18.

Lang, Roberto M., Uri Elkayam, Daniel Krauss, et al.. (1997). Comparative Effects of Losartan and Enalapril on Exercise Capacity and Clinical Status in Patients With Heart Failure fn1fn1This study was supported by a grant from Merck Research Laboratories, West Point, Pennsylvania.. Journal of the American College of Cardiology. 30(4). 983–991. 88 indexed citations

19.

Lang, Roberto M., Robert DiBianco, Stephen S. Gottlieb, et al.. (1994). First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patient with heart failure: A double-blind, randomized, multicenter study. American Heart Journal. 128(3). 551–556. 13 indexed citations

20.

Garrard, Judith, Lukas Makris, Signe S Cooper, et al.. (1992). Longitudinal Study of Psychotropic Drug Use by Elderly Nursing Home Residents. Journal of Gerontology. 47(6). M183–M188. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact